AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: While ROS may definitely increase the genomic instability of CML cells and contribute to deregulation of DNA repair (29), the proposed pathways of ROS induction via STAT5 and PI3K/Akt were found to be inhibited in KCL-22 and CML-T1 cells treated with imatinib and remained diminished even after mutation acquisition, making their contribution to de novo mutagenesis questionable.